Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a “gray zone”?

Author:

McRae-McKee Kevin1,Udeh-Momoh Chinedu T.2,Price Geraint2,Bajaj Sumali1,de Jager Celeste A.2,Scott David3,Hadjichrysanthou Christoforos1,McNaughton Emily1,Bracoud Luc4,Ahmadi-Abhari Sara2,de Wolf Frank1,Anderson Roy M.1,Middleton Lefkos T.25,

Affiliation:

1. Department of Infectious Disease Epidemiology; School of Public Health, Imperial College London; London United Kingdom

2. Ageing Epidemiology (AGE) Research Unit; School of Public Health, Imperial College London; London United Kingdom

3. Bioclinica, Inc.; Newark CA USA

4. Bioclinica, Inc.; Lyon France

5. Imperial College Healthcare NHS Trust; London United Kingdom

Funder

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Araclon Biotech

BioClinica

Biogen

Bristol-Myers Squibb

CereSpir, Inc.

Cogstate

Eisai Inc.

Elan Pharmaceuticals, Inc.

Eli Lilly and Company

EuroImmun

Roche

Genentech

Fujirebio US

GE Healthcare

IXICO Ltd.

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson and Johnson Pharmaceutical Research and Development

Lumosity

H. Lundbeck A/S

Merck

Meso Scale Diagnostics

NeuroRx Research

Neurotrack Technologies

Novartis Pharmaceuticals Corporation

Pfizer

Piramal Imaging

Servier

Takeda Pharmaceutical Company

Transition Therapeutics

Canadian Institutes of Health Research

ADNI

UK Medical Research Council

Department for International Development

Janssen

Takeda

AstraZeneca

Novartis

UCB Pharmaceuticals

BioClinica, Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd

Genentech, Inc.

Fujirebio

Johnson & Johnson Pharmaceutical Research & Development LLC.

Lundbeck

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

Pfizer Inc.

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3